Search
Noscapine
go.drugbank.com/drugs/DB06174ApprovedCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A InhibitorsZosuquidar
go.drugbank.com/drugs/DB06191InvestigationalIts action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Categories: P-glycoprotein inhibitorsRufinamide
go.drugbank.com/drugs/DB06201ApprovedRufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersVadimezan
go.drugbank.com/drugs/DB06235InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZiconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail Conus magus comprising 25 amino acids with three disulphide bonds. Other such peptides, collectively termed conotoxins, exist, and some have shown eff...
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the E...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAVE9633
go.drugbank.com/drugs/DB06318InvestigationalAVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIndisulam
go.drugbank.com/drugs/DB06370InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates